The anti-inflammatory drug colchicine at a dose of 0.5 mg/day significantly reduced the risk of ischaemic cardiovascular (CV) events in individuals with a recent myocardial infarction (MI), according to results of the COLCOT* trial presented at AHA 2019.
Use of the PCSK9* inhibitor alirocumab in acute coronary syndrome (ACS) patients on a background of high-intensity statin treatment delivers reductions in total hospitalizations and death with corresponding gains in days alive and out of hospital (DAOH), according to the results of prespecified and posthoc analyses of the ODYSSEY OUTCOMES** trial presented at the American Heart Association (AHA) 2019 Scientific Sessions.
Treatment with the PCSK9 inhibitor alirocumab reduces the risk of stroke in patients with recent acute coronary syndrome (ACS) and dyslipidaemia despite intensive statin therapy, regardless of their baseline low-density lipoprotein cholesterol (LDL-C) and history of cerebrovascular disease (CeVD), according to the results of the ODYSSEY OUTCOMES trial presented at the 2019 Scientific Sessions of the American Heart Association.
The combination of pomalidomide and dexamethasone (PomDex) is effective against relapsed/refractory multiple myeloma (MM) in Asians, according to a recent study. The addition of cyclophosphamide may further supplement its effects.
The net clinical benefit (NCB) of anticoagulation use in patients with atrial fibrillation (AF) appears to decrease with advancing age, and this decline can be attributed to competing mortality risk, as shown in a study.
Evolocumab treatment over 2.3 years does not seem to benefit atherosclerotic patients without multiple clinical risk factors or high genetic risk, and these individuals also have a low event rate. However, those with high genetic risk, irrespective of clinical risk, have a high event rate and receive large relative and absolute benefit from this therapy, thus alleviating such risk, according to a study presented at the 2019 Scientific Sessions of the American Heart Association.
From September to November 2019, the iMANAGE (Integrated Management of Non-Communicable Diseases in Non-Governmental Establishments) programme conducted a three-part workshop series in Kuala Lumpur for Klang Valley general practitioners and pharmacists working in the private sector.
A 3-year sustained reduction of serum uric acid (SUA) with allopurinol was of no benefit to type 1 diabetes (T1D) patients with mild-to-moderate kidney disease, according to the PERL* study presented at the ASN 2019 Meeting.
Elvira Manzano, Roshini Claire Anthony,
01 Oct 2019
The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.
Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US.
Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]